Revised rules requiring pesticide testing for cannabis products were finally adopted by the board, and a variety of critical public remarks preceded a lengthy response from the chair.
Staff explained the session was “coming to an end” and discussed active legislation—including a new cannabinoid regulation bill–as well as budget provisos which could affect WSLCB.
Staff briefed on a bill with complex changes to recommended cannabis tax appropriations before testimony emphasized benefits for transparency, social equity, and local governments.
Four synthesized cannabinoid regulation bills had been introduced after cutoff, cannabis-related amendments were in the operating budget, and new QC rules were imminent.
Testimony on a bill to exempt registered medical cannabis patients from the excise tax on DOH compliant products was supportive and elicited several questions from lawmakers.
The work group welcomed new members, discussed previously approved recommendations, and hosted an open discussion on potential new license types for equity applicants.
The agency’s top lobbyist reviewed legislative activity, diving deeper into a new cannabinoid regulation bill and work to salvage components of unsuccessful social equity legislation.
Committee members heard positive testimony on a bill to increase penalties for cannabis retail robberies, and asked questions about the frequency of incidents and other solutions.
As the timeline for legislation became more compressed, committees crammed bills for action - while the WSLCB cannabinoid regulation bill was granted a second chance to NTIB.
An update on the cannabis compliance reporting transition outlined plans for a second phase of development and prompted discussion about the eventual need for enforcement.